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INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global 
pandemic and has affected around 5.8 million people worldwide 
with over 360 000 deaths between 31 December 2019 and 
1 June 2020.(1) Cardiovascular manifestations of COVID-19 
include acute coronary syndromes, heart failure, thrombo-
embolic events, cardiogenic shock, cardiac arrest and arrhyth-
mias.(2) This review will focus on the epidemiology, challenges 
to the management of arrhythmias in patients with COVID-19, 
and highlight the potential risks of novel treatments that pro-
long the QT interval. 
EPIDEMIOLOGY
The incidence of arrhythmias in patients with COVID-19 is 
unknown. There is preliminary evidence that palpitations and 
arrhythmias are a common presenting symptom or manifestation 
of COVID-19 infection. In a study from Wuhan, China, 10 
(7.3%) of 137 patients had reported palpitations as an initial 
symptom.(3) In another study of 138 patients hospitalised with 
COVID-19, arrhythmias (unspecified) were reported in 23 
(16.7%) patients – 7 (7%) patients in the non-ICU setting versus 
16 (44%) in patients admitted to ICU.(4) 
CHALLENGES TO ARRHYTHMIA 
MANAGEMENT IN PATIENTS WITH COVID-19
COVID-19 brings some unique challenges to arrhythmia 
management. These challenges are somewhat different to 
traditional arrhythmia management, depending on the clinical 
situation. There are patients with arrhythmias caused by 
COVID-19 (either by the infection itself or therapies given), 
and those with underlying arrhythmias (in either structurally 
normal or abnormal hearts) who are concurrently infected with 
COVID-19. There is some overlap between these 2 groups.
As with many other facets of the disease, infection with 
COVID-19 can cause a variety of arrhythmias. The most feared 
of these are malignant ventricular arrhythmias (ventricular 
tachycardia and fibrillation), which can be found in 5.9% of 
cases.(6) Postulated mechanisms include the high level of 
circulating cytokines (particularly IL-6) seen in severe cases of 
COVID-19 infection, hypoxia-induced apoptosis and COVID-19 
myocarditis, all of which may result in myocardial damage and 
cause atrial or ventricular arrhythmias.(7) The management of 
these arrhythmias is influenced by the high risk environment in 
which they occur.
ARRHYTHMIA MANAGEMENT IN COVID-19 
POSITIVE PATIENTS
SARS-CoV-2 is a highly infectious virus which can be exac-
erbated by aerosolisation of viral particles with high flow 
oxygen, bronchoscopy, open tracheal suctioning, intubation, 







Arrhythmias can be a clinical manifestation of 
COVID-19 infection. COVID-19 infection can also be a 
precipitant of known arrhythmias which can increase 
the risk of morbidity and mortality. Management of 
arrhythmias should generally follow standard guidelines 
of arrhythmia management. Catheter ablation in the 
midst of the COVID-19 pandemic should be limited to 
arrhythmias that are immediately life-threatening or 
which may affect prognosis in the short-term. Some 
novel treatments like chloroquine, hydroxychloroquine 
and azithromycin can prolong the QT interval and pre-
dispose patients to life-threatening arrhythmias.  
SAHeart 2020;17:362-369
* Cardiac Clinic, University of Cape Town and Groote Schuur 
Hospital, Observatory, Cape Town, South Africa
# Stellenbosch University and Tygerberg Hospital, Bellville, 
South Africa
† Sunninghill Hospital, Johannesburg, South Africa
Address for correspondence: 
Associate Professor Ashley Chin
Cardiac Clinic




















doscopy, or transoesophageal echocardiography. It is recom-
mended that as few healthcare practitioners as possible be 
exposed to clinically high risk areas, by taking measures such as 
limiting the number of people on ward rounds.(8) This recom-
mendation extends to referrals and consultations, where the 
recommendation is that as little time be spent face-to-face at 
the patient’s bedside as possible, with most electrophysiology 
(EP) referrals being managed by reviewing the patient’s chart 
and monitoring data including the ECG.(8) 
As ICUs and other high-care facilities where COVID-19 patients 
are being treated become overwhelmed, the first considera-
tion is to decide which patients need continuous cardiac mon-
itoring. It is recommended that a baseline history, examination 
and risk assessment for arrhythmic events be performed on all 
patients. The exact contribution of COVID-19 to arrhythmia 
development in patients who are asymptomatic or only mildly 
symptomatic is not known. In those patients who are ill enough 
to be admitted to hospital, it is recommended that a baseline 
ECG (ideally a 12 lead ECG, but a single or multiple lead ECG 
from telemetry will suffice if normal) should be obtained on 
admission to hospital (unless a baseline ECG taken within the 
last month is available, in which case this should be used).(9) 
Hypoxia and electrolyte abnormalities are known to contribute 
to arrhythmia risk and it is recommended that the K+ be 
maintained at above 4mmol/l and the Mg2+ be maintained at 
above 2mg/dl.(9) In the absence of documented cardiac 
arrhythmias, suspected myocardial ischemia, or other standard 
indications, continuous ECG monitoring is not required. If 
available, continuous ECG monitoring can be used in lieu of 
repeated 12 lead ECGs to minimise staff exposure to patients 
and to preserve personal protective equipment (PPE).(10) 
For the diagnosis of arrhythmias, a 12 lead ECG is considered 
the gold standard but a rhythm strip can also be used. The most 
common arrhythmia in patients with COVID-19 is sinus 
tachycardia, but the most common pathologic arrhythmias 
include atrial fibrillation (AF), atrial flutter (AFL), monomorphic 
ventricular tachycardia (MMVT) and polymorphic ventricular 
tachycardia (PMVT).(10) 
The management of specific arrhythmias in a patient with 
COVID-19 infection is similar to that of patients without 
COVID-19 infection. In a patient with a haemodynamically 
unstable arrhythmia (whether it be supraventricular or ven-
tricular), external direct current (DC) cardioversion is the 
treatment of choice, followed by the initiation of medical 
therapy as appropriate. In patients who are haemodynamically 
stable, the recommendation is that medical therapy be initiated 
according to standard guidelines for that condition (please refer 
to the relevant guidelines). In stable patients who respond to 
medical therapy, catheter ablation (if indicated) should be 
postponed until such time as the patient has recovered from 
COVID-19 infection.(8)
A few specific aspects of management deserve special attention:
Torsades de Pointes (TdP): 
 ■ For patients with a single episode of TdP, treatment with IV 
magnesium along with correction of metabolic/electrolyte 
derangements and/or stopping all QT-prolonging drugs 
may be sufficient. The patient should be carefully monitored 
until electrolytes are normalised and the QT interval nor-
malises. This is particularly relevant in patients taking chloro-
quine, hydroxychloroquine or a macrolide antibiotic as 
novel therapy for COVID-19 (see below).
 ■ For patients with multiple self-terminating episodes of TdP, 
the same therapies are utilised as in patients with a single 
episode (i.e. IV magnesium, correction of metabolic/
electrolyte derangements, and/or removal of any inciting 
medications), along with additional interventions to increase 
the heart rate, which include overdrive pacing and/or IV 
isoproterenol infusion (where available).(10) 
Atrial fi brillation (AF) and atrial fl utter (AFL):
 ■ Rate control with B-blockers or non-dihydropyridine cal-
cium channel blockers should be first-line therapy.
 ■ Anticoagulation should be considered according to the 
CHA2DS2-VASc score as per standard practice.
 ■ Consideration should be given to stopping anti-arrhythmic 
drugs with QT-prolonging effects, should specific therapies 
for COVID-19, which also prolong the QT, be necessary.
 ■ The combination of amiodarone with hydroxychloroquine 
and azithromycin should be avoided.
 ■ Transoesophageal echocardiography (TOE) should be 
avoided as far as possible, with elective cardioversion either 
being delayed until the patient has recovered from 
COVID-19 infection, or after 3 weeks of effective anti-
coagulation.
A definitive rate or rhythm control strategy (including the 
potential for catheter ablation), should be reviewed once the 
COVID-19 infection has resolved.(2) 
Monomorphic ventricular tachycardia (MMVT):
 ■ A point of care transthoracic echocardiogram should be 
considered.
 ■ Coronary angiography or other investigations should be 
considered based on the clinical likelihood of an acute 
coronary syndrome,  myocarditis or cardiomyopathy.
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 ■ Amiodarone is the drug of choice, should the patient have 
recurrent MMVT.
 ■ Caution should be exercised in adding amiodarone to 
other therapies that prolong the QT (review the necessity 
for other QT-prolonging medications).
 ■ The need for implantation of a secondary prevention 
implantable cardioverter-defibrillator (ICD) should be 
reviewed once the COVID-19 infection has cleared.(2) 
Paroxysmal supra-ventricular tachycardias (SVT):
 ■ Vagal manoeuvres and adenosine can be safely applied.
 ■ Medical therapy with B-blockers (or non-dihydropyridine 
calcium channel blockers where B-blockers are contra-
indicated) should be initiated.
 ■ The indication for catheter ablation should be assessed 
after the COVID-19 pandemic.(2) 
Channelopathies:
 ■ Patients with inherited arrhythmia syndromes (like 
congenital Long QT syndrome (LQTS) and Brugada syn-
drome) are potentially at increased risk of ventricular 
arrhythmias and sudden death with COVID-19 infection.(11) 
 ■ Congenital LQTS patients with COVID-19 are potentially 
at increased risk of TdP/VF because of other factors that 
prolong the QT interval. Factors include electrolyte abnor-
malities (hypokalaemia, hypomagnesaemia and hypo-
calcaemia), use of QT-prolonging drugs and liver and renal 
disease. LQTS type 2 patients may also be at increased risk 
because of fever (similar to Brugada syndrome – see 
below). The use of any novel therapies for COVID-19 
which prolong the QT interval should not be used in 
patients with congenital LQTS.(11)
 ■ Brugada syndrome – it is well known the sodium channels 
are temperature sensitive. Fever can block sodium channels, 
which can result in worsening of the Brugada pattern on 
ECG and increase the risk of sudden death in patients with 
a type 1 Brugada pattern. For these reasons, fever in 
patients with Brugada syndrome and COVID-19, should be 
treated promptly with paracetamol.(12)
TRIAGE AND MANAGEMENT OF 
ARRHYTHMIAS AND OTHER 
ELECTROPHYSIOLOGY PROCEDURES 
DURING THE COVID-19 PANDEMIC
The principles underlying the management of patients with 
cardiac arrhythmias during the COVID-19 pandemic are largely 
governed by the need to limit the peri-procedural COVID-19 
exposure for both the EP team and the patients.(8) This 
necessitates the categorisation of EP procedures into elective, 
urgent or emergent. All elective ablation and cardiac device 
implantation procedures should be postponed, and antiar-
rhythmic medications should be reviewed and intensified if 
necessary, to allow control of symptomatic arrhythmia recur-
rences during the COVID-19 pandemic period. CIED follow-up 
should be done via remote monitoring in all patients, where 
possible.(2) 
Procedures can be classified as summarised in Table 1:(2,8)
PROTECTING STAFF AND THE 
APPROPRIATE USE OF PERSONAL 
PROTECTIVE EQUIPMENT (PPE)
When treating patients during the COVID-19 pandemic, it is 
important to be aware of the risk of exposure to the EP team, 
during both consultations and invasive procedures. As already 
mentioned, face-to-face consultations should be limited and 
many consultations can be done by, for example, a review of 
the patient’s chart and ECGs.(8) When community spread is 
high, it is prudent to consider all patients potentially infected 
with COVID-19 and to take appropriate precautions to protect 
the healthcare workers. Guidelines for the use of PPE are likely 
to differ slightly depending on the institution and the availability 
of PPE, but some basic principles are common to all. When 
considering the use of PPE, one needs to consider both the 
patient being treated and the procedure being done, with the 
highest risk being an aerosol-generating procedure in a known 
COVID-19 infected patient, and the lowest risk being a simple 
clinical examination in a known COVID negative patient.
Most institutions have guidelines for the use of PPE stratified by 
the combined risk. There are general measures which should 
be taken in all situations, and specific guidelines for PPE in 
addition to these general measures.
General measures to prevent infection(13)
Hand hygiene
Transmission can be greatly reduced by an increased frequency 
of hand hygiene using the “World Health Organisation (WHO) 
5 Moments for Hand Hygiene”:
 ■ Wash hands with soap and water for 20 seconds or use 
alcohol-based hand sanitiser after each patient contact and 
after contact with frequently touched surfaces (e.g. door 
handles, keyboards, phones, work surfaces).
 ■ Respiratory etiquette: cough and sneeze into a flexed 
elbow or into a tissue (immediately discard the soiled tissue 













 ■ Avoid touching your mouth, eyes and nose with gloved or 
bare hands. Wash hands before doing so.
 ■ Avoid physical contact such as handshakes and hugs.
 ■ Social distancing: maintain a distance of at least 1.5 - 2 
metres away from other people.
 ■ Environmental cleaning: frequently touched surfaces and 
equipment in clinical areas should be cleaned and disinfected 
twice daily (minimum), and after every use.
 ■ Work clothes: Remove your work clothes at the workplace 
and place in a plastic bag to take home, and clean with a 
warm wash. Or, remove your work clothes immediately 
upon arriving home, and clean with a warm wash. Always 
wash your hands after removing your work clothes.
Types of PPE and the clinical situations in which they 
should be applied:(2,9,13) 
 ■ This is summarised in Table II.
 ■ All healthcare workers should familiarise themselves with 
the correct donning and doffing procedures (aided by a 
donning and doffing buddy system and visible posters 
where possible).
Recommendations for invasive procedures:(2,8,14)
 ■ Emergency and urgent invasive electrophysiology pro-
cedures are often performed in patients at high risk of 
haemodynamic instability, cardioversion and potentially 
cardio-pulmonary resuscitation.
 ■ As such, the recommendation is that full PPE be donned 
for these procedures.
TABLE I: Risk stratification of electrophysiology procedures.
Emergency Urgent Elective 
Catheter ablation VT ablation for electrical storm
AF/AFL with tachycardia induced 
cardiomyopathy, refractory to medical 
therapy including cardioversion
WPW syndrome with fast 
pre-excited AF
VT ablation for medically 
refractory recurrent VT
AF/AFL ablation for medically refractory 
AF/AFL (including cardioversion), with 
recurrent emergency room visits
SVT ablation for medically refractory 




SVT ablation/diagnostic EP testing
CIED procedures Generator change in a patient where 
EOL present or imminent
Secondary prevention ICD
PM for high degree AVB or SND 
with long pauses
CRT implant in a patient with severe, 
medically refractory heart failure
Lead revision with lead malfunction in a 
pacemaker-dependent patient or in a 
patient with an ICD receiving 
inappropriate shocks
Lead extraction for infection
Generator change in a patient 
where ERI present
Primary prevention ICD in patient 
with very high risk of arrhythmias
Generator change in a patient where 
ERI >6 weeks
Primary prevention ICD
PM for SND, Mobitz I AVB, stable 
non-high degree AVB, or tachy-brady 
syndrome in mildly symptomatic patient
CRT implant or device upgrade 
in stable patient
Lead revision for 
asymptomatic malfunction
Lead extraction in a patient 
without infection
Other Cardioversion of medically refractory 
atrial arrhythmias with rapid 
ventricular rates
TOE for urgent cardioversion
Cardioversion of stable arrhythmias 
with well tolerated symptoms
TOE for routine assessment of valves or 
LAA closure devices and cardioversion 






VT = ventricular tachycardia, PVC = premature ventricular complex, AF = atrial fibrillation, AFL = atrial flutter, WPW = Wolff-Parkinson-White, SVT = supraventricular tachycardia, 
EP = electrophysiology, CIED = cardiovascular implantable electronic device, EOL = end of life, ERI = elective replacement indicator, ICD = implantable cardioverter-defibrillator, 
PM = pacemaker, AVB = atrio-ventricular block, SND = sinus node disease, CRT = cardiac resynchronisation therapy, TOE = tranoesophageal echocardiogram, LAA = left atrial 
appendage, ILR = implantable loop recorder.
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(nurses, doctors, EMS) 
providing direct care 
to COVID-19 patients 




(admin staff, catering 
staff) coming into 






(cleaners) coming into 














Change when leaving 
COVID-19 area
Reusable long rubber 
utility cleaning gloves 
(ideally up to elbow)




Masks Surgical mask 
for general care of 
COVID-19 patients






when within <1m of a 
patient with respiratory 
symptoms (one per shift, 
if integrity maintained)
Surgical mask
when within <1m of a 
patient with respiratory 
symptoms
Surgical mask
worn when in contact 
with others
None
Aprons Change when visibly 
contaminated
Discard after aerolisation 
procedure
Change when leaving 
COVID-19 area
Change after each work 
session (in absence of 
clinical contact)
None None
Eye cover Face shield/goggles
Wash clean, disinfect 
and reuse
None Face shield/goggles
Wash clean, disinfect 
and reuse
None None
EMS = emergency medical services.
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 ■ Full PPE in the cardiac catheterisation laboratory includes a 
sterile gown, double gloves and shoe covers.
POTENTIAL THERAPIES FOR COVID-19 AND 
THE RISK OF QT PROLONGATION AND 
TORSADE DE POINTES
When the new disease caused by COVID-19 started to appear, 
initially in late 2019 in China, and subsequently in the rest of 
the world from early 2020 onwards, much emphasis was 
placed on finding therapies to prevent, modulate and poten-
tially treat this new problem. A lot of the early work came 
from China and suggested that hydroxychloroquine/chloro-
quine together with azithromycin might be very effective in 
this regard, but immediately cardiologists, and especially those 
dealing with arrhythmias, became extremely concerned about 
the risk of malignant pro-arrhythmias due to the QT-prolonging 
effects of these drugs individually, and especially in combination, 
with the risk of TdP. Almost immediately, rhythm societies 
from around the world published guidelines with regard to the 
use of potentially QT-prolonging drugs and guidelines with 
regard to assessment in this regard, with the American societies 
including the Heart Rhythm Society, together with the American 
College of Cardiology and the American Heart Association 
guidelines probably being the most prominent.(15) 
However, a number of other drugs used in the treatment of 
patients with COVID-19, and especially those who are seriously 
ill, also have possible QT-prolonging effects. Unfortunately, 
underlying cardiovascular disease and hypertension also signi-
ficantly increase the risk of serious COVID-19 related disease, 
in a population already at risk of significant arrhythmias. In 
addition, one has to remember that the disease itself is asso-
ciated with significant direct cardiovascular effects, particularly 
myocarditis, and that some of these patients will become 
seriously ill, which in itself predisposes to both atrial and 
ventricular tachyarrhythmias and to bradyarrhythmias. Further-
more, the acute systemic inflammatory response seen in these 
patients also significantly increases the risk of arrhythmias, and 
the combination of QT-prolonging drugs and the serious 
underlying comorbidities combined significantly increases the 













It would seem as though the initial enthusiasm for the com-
bination of hydroxychloroquine/chloroquine and azithromycin 
brought about by early Chinese publications and reports and 
the French studies and other reviews suggesting decreased 
viral load and potential clinical benefit, have not been borne 
out.(16-18) More recent studies both from North and South 
America, and publications from registries in high-profile journals 
have in fact suggested that there were significant levels of QT 
prolongation and an increased risk of arrhythmias – with efficacy 
not really borne out.(5,19,20) In many countries these drugs have 
therefore been withdrawn from guidelines, but have remained 
in the guidelines of a number of countries with some high-
profile figures worldwide, with these recently also espousing 
the use of these drugs.
A number of other drugs have however been suggested as 
possible therapies for COVID-19, including the antiviral agent 
remdesivir, the HIV drugs lopinavir and ritonavir, the influenza 
drug favipravir, together with ribavirin and interferon beta 1b, 
and other agents to modify the systemic inflammatory 
response.(21) A number of these are presently in various states 
of investigation with regard to their usefulness and efficacy in 
the management of COVID-19. A significant number of these 
have also been associated with, or are potentially implicated in 
QT segment prolongation, with arrhythmias noted as side-
effects of some of these drugs.
One also has to remember that some of the agents used in 
patients on ventilators for sedation and in ill patients for 
nausea, together with a number of antibiotics, have also been 
implicated in QT segment prolongation and therefore com-
bination therapies have to be looked at extremely carefully in 
patients on polypharmacy to try and prevent the use of mul-
tiple QT-prolonging drugs.
Keeping track of all of the potential QT-prolonging drugs can 
be very problematic and therefore we would recommend the 
use of a website and smart phone application specifically 
developed in this regard, https://www.crediblemeds.org/ and 
the crediblemeds app. Both of these are kept up-to-date on a 
regular basis, particularly currently.
Calculation of the QT interval itself has been shown to be 
poorly performed in general, even by experienced people, and 
is therefore difficult, and automated ECG algorithms are often 
incorrect.(22) It is important to note that the QT should be 
calculated from the beginning of the QRS complex and using 
the tangent method to calculate the end of the T wave, and 
then corrected using the preceding RR interval, using 1 of 
the standard calculations, most commonly Bazett’s formula – 
QTc = QT/square root of the preceding RR interval – see 
Figure 1. Some averaging over a number of beats may be 
needed, especially when the rhythm is irregular, and calculating 
the QT when the QRS complex is broad is also challenging.
One challenge in correcting the QT, particularly in ill patients 
with sinus tachycardia, can be choosing a correction formula. 
The most common correction formula, Bazett’s formula, is 
inaccurate at heart rates less than 60 or greater than 110bpm 
and has a tendency to overestimate the QTc, possibly leading 
to unnecessary discontinuation of therapy. Alternative formulas 
have shown better accuracy and less heart rate dependency, 
but can be more tricky to calculate.
The North American guidelines suggest:(15) 
 ■ Electrocardiographic/QT interval monitoring;
 ■ Withhold hydroxychloroquine and azithromycin in patients 
with baseline QT prolongation (e.g. QTc ≥500ms) or with 
known congenital long QT syndrome;
 ■ Monitor cardiac rhythm and QT interval; withdrawal of 
hydroxychloroquine and azithromycin if QTc exceeds a 
present threshold of 500ms;
FIGURE 1: The QT interval should be calculated from the 
beginning of the QRS complex and then use the tangent method 
to calculate the end of the T wave, and then corrected using the 
RR interval and the Bazett’s formula. In this example, a tangent 
line is drawn with the downslope of the T wave, and the end of 
the QT interval is taken where it intersects the isoelectric line. 
The preceding R-R interval of the measured QT interval should 
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 ■ In patients critically ill with COVID-19 infection, frequent 
caregiver contact may need to be minimised, so optimal 
electrocardiographic interval and rhythm monitoring may 
not be possible; in these cases, some have suggested that 
the use of telemetry may be used as a compromise to 
prevent frequent caregiver contact;
 ■ Correction of hypokalaemia >4mmol/L and hypomag-
nesemia >2mg/dL; and
 ■ Avoid other QTc-prolonging agents, whenever feasible.
Further experience going forward will undoubtedly yield 
further information with regard to the risk of arrhythmias, with 
therapies being evaluated for the treatment of COVID-19. It is 
also appropriate to review how to accurately measure the QT 
interval and to remember the potential QT-prolonging effects 
of many of the drugs that we use. Furthermore, it may prompt 
us to look more carefully at some therapies that are known to 
prolong the QT interval where ECG monitoring is not under-
taken, prior to its initiation and during the course of treatment.
CONSIDERATIONS FOR THE USE OF 
ANTIARRHYTHMIC DRUGS AND 
ANTICOAGULATION IN PATIENTS 
WITH COVID-19
When using antiarrhythmic drugs in these patients, standard 
guidelines should apply, always remembering that the antiar-
rhythmic drugs themselves have proarrhythmic effects and in 
many cases can themselves significantly prolong the QT interval.
In terms of oral anticoagulation, it is inevitable that many 
patients who develop severe COVID-19 related disease will 
already have been on oral anticoagulation, either with vitamin K 
antagonists or with direct oral anticoagulants. In addition, there 
is increasing evidence that COVID-19 promotes thrombosis 
and that this mechanism may be a significant contributor to 
both morbidity and mortality.(23,24) In this regard, a number of 
trials have been initiated looking at the use of anticoagulation, 
predominantly in the form of low molecular weight heparin, 
in the management of these patients. A recently published 
research letter from New York has elicited some controversy, 
but suggested that in patients requiring mechanical ventila-
tion, in-hospital mortality and overall survival was significantly 
improved using a combination of heparin, low molecular weight 
heparin and direct oral anticoagulants.(25) This was a retro-
spective study and was not randomised and further randomised 
trials are ongoing. Of note is that an elevated risk of bleeding 
events associated with oral anticoagulation has been highlighted 
in a number of studies. One recent publication suggested that 
patients on vitamin K antagonists who are hospitalised with 
COVID-19 show high instability of INR measurements prob-
ably related to alterations in vitamin K metabolism, together 
with polypharmacy and renal and liver dysfunction.(26) In addi-
tion, there may be significant pharmacological interactions with 
the direct oral anticoagulants. 
At present it would seem as though anticoagulation should be 
carefully reassessed in those who present with COVID-19 and 
who are on oral anticoagulation, particularly regarding how this 
is administered and monitored, but that some form of anti-
coagulation may well be beneficial in patients with significant 
COVID-19 disease. Again, further information will undoubtedly 
be forthcoming in this regard in the short to medium term.
CONCLUSION
Arrhythmias can complicate the clinical course of patients with 
COVID-19 infection in a significant number of patients. Manage-
ment of arrhythmias should generally follow standard guide-
lines of arrhythmia management. Catheter ablation in the midst 
of the COVID-19 pandemic should be limited to arrhythmias 
that are immediately life-threatening or which may affect prog-
nosis in the short term. Numerous COVID-19 therapies are 
under investigation at present. Currently no therapy has shown 
to be effective in the treatment of COVID-19 and some may 
prolong the QT interval which may predispose patients to life-
threatening arrhythmias. Careful monitoring of QTc intervals is 
essential in patients at risk and potential therapies that prolong 
the QT interval should be restricted to clinical trials. 
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